Epigenetic inactivation of BRCA1 through promoter hypermethylation and its clinical importance in triple-negative breast cancer

Clinical Breast Cancer

Volumn 15, Issue 6, 2015, Pages 498-504

  Yamashita, Nami ^a   Tokunaga, Eriko ^a   Kitao, Hiroyuki ^a   Hitchins, Megan ^b   Inoue, Yuka ^a   Tanaka, Kimihiro ^a   Hisamatsu, Yuichi ^a   Taketani, Kenji ^a   Akiyoshi, Sayuri ^a   Okada, Satoko ^a   Oda, Yoshinao ^a   Saeki, Hiroshi ^a   Oki, Eiji ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal like breast cancer; BRCA1; Breast cancer; Promotor methylation; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; MESSENGER RNA; BRCA1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DNA METHYLATION; EPIGENETICS; GENE INACTIVATION; GERMLINE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; RESTRICTION MAPPING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC MUTATION; SURVIVAL RATE; SYSTEMIC THERAPY; TRANSCRIPTION INITIATION SITE; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; BIOSYNTHESIS; FEMALE; GENETIC EPIGENESIS; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84947020790     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2015.06.009     Document Type: Article

References (44)

1. S. Cleator, W. Heller, and R.C. Coombes Triple-negative breast cancer: therapeutic options Lancet Oncol 8 2007 235 244
2. B.D. Lehmann, J.A. Bauer, X. Chen, and et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 2011 2750 2767
3. C.M. Perou, T. Sorlie, M.B. Eisen, and et al. Molecular portraits of human breast tumours Nature 406 2000 747 752
4. T. Sorlie, R. Tibshirani, J. Parker, and et al. Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci U S A 100 2003 8418 8423
5. C. Oakman, G. Viale, and A. Di Leo Management of triple negative breast cancer Breast 19 2010 312 321
6. N. Turner, A. Tutt, and A. Ashworth Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 2004 814 819
7. R.D. Kennedy, J.E. Quinn, P.B. Mullan, P.G. Johnston, and D.P. Harkin The role of BRCA1 in the cellular response to chemotherapy J Natl Cancer Inst 96 2004 1659 1668
8. M.S. Huen, S.M. Sy, and J. Chen BRCA1 and its toolbox for the maintenance of genome integrity Nat Rev Mol Cell Biol 11 2010 138 148
9. M.L. Li, and R.A. Greenberg Links between genome integrity and BRCA1 tumor suppression Trends Biochem Sci 37 2012 418 424
10. Q. Zhu, G.M. Pao, A.M. Huynh, and et al. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing Nature 477 2011 179 184
11. E.B. Claus, N. Risch, and W.D. Thompson Genetic analysis of breast cancer in the cancer and steroid hormone study Am J Hum Genet 48 1991 232 242
12. E.L. Schubert, M.K. Lee, H.C. Mefford, and et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2 Am J Hum Genet 60 1997 1031 1040
13. D.F. Easton, D. Ford, and D.T. Bishop Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Am J Hum Genet 56 1995 265 271
14. P.A. Futreal, Q. Liu, D. Shattuck-Eidens, and et al. BRCA1 mutations in primary breast and ovarian carcinomas Science 266 1994 120 122
15. M.E. Thompson, R.A. Jensen, P.S. Obermiller, D.L. Page, and J.T. Holt Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression Nat Genet 9 1995 444 450
16. A. Perez-Valles, M. Martorell-Cebollada, E. Nogueira-Vazquez, J.A. Garcia-Garcia, and E. Fuster-Diana The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study J Clin Pathol 54 2001 476 480
17. C.A. Wilson, L. Ramos, M.R. Villasenor, and et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas Nat Genet 21 1999 236 240
18. S.B. Baylin, J.G. Herman, J.R. Graff, P.M. Vertino, and J.P. Issa Alterations in DNA methylation: a fundamental aspect of neoplasia Adv Cancer Res 72 1998 141 196
19. P.A. Jones, and P.W. Laird Cancer epigenetics comes of age Nat Genet 21 1999 163 167
20. J.C. Rice, K.S. Massey-Brown, and B.W. Futscher Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells Oncogene 17 1998 1807 1812
21. M. Esteller, J.M. Silva, G. Dominguez, and et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors J Natl Cancer Inst 92 2000 564 569
22. J.C. Rice, H. Ozcelik, P. Maxeiner, I. Andrulis, and B.W. Futscher Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens Carcinogenesis 21 2000 1761 1765
23. E. Matros, Z.C. Wang, G. Lodeiro, A. Miron, J.D. Iglehart, and A.L. Richardson BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles Breast Cancer Res Treat 91 2005 179 186
24. F. Magdinier, S. Ribieras, G.M. Lenoir, L. Frappart, and R. Dante Downregulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region Oncogene 17 1998 3169 3176
25. H. Konishi, M. Mohseni, A. Tamaki, and et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells Proc Natl Acad Sci U S A 108 2011 17773 17778
26. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind TNM Classification of Malignant Tumors 7th ed. 2009 Wiley-Blackwell Oxford, UK
27. E. Tokunaga, E. Oki, S. Oda, and et al. Frequency of microsatellite instability in breast cancer determined by high-resolution fluorescent microsatellite analysis Oncology 59 2000 44 49
28. P.C. Fong, D.S. Boss, T.A. Yap, and et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
29. E. Tokunaga, Y. Kimura, E. Oki, and et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients Int J Cancer 118 2006 284 289
30. P.H. Tan, B.H. Bay, G. Yip, and et al. Immunohistochemical detection of Ki-67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death Mod Pathol 18 2005 374 381
31. T.O. Nielsen, F.D. Hsu, K. Jensen, and et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 2004 5367 5374
32. S.D. Merajver, T.M. Pham, R.F. Caduff, and et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours Nat Genet 9 1995 439 443
33. G. Sourvinos, and D.A. Spandidos Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors Biochem Biophys Res Commun 245 1998 75 80
34. P.A. Jones, and S.B. Baylin The fundamental role of epigenetic events in cancer Nat Rev Genet 3 2002 415 428
35. Z. Xiong, and P.W. Laird COBRA: a sensitive and quantitative DNA methylation assay Nucleic Acids Res 25 1997 2532 2534
36. E.H. Lips, L. Mulder, A. Oonk, and et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers Br J Cancer 108 2013 2172 2177
37. T. Ignatov, A. Poehlmann, A. Ignatov, and et al. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC Breast Cancer Res Treat 141 2013 205 212
38. R. Ben Gacem, M. Hachana, S. Ziadi, and et al. Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients Cancer Epidemiol 36 2012 190 197
39. S. Staff, J. Isola, and M. Tanner Haplo-insufficiency of BRCA1 in sporadic breast cancer Cancer Res 63 2003 4978 4983
40. B.J. Miller, D. Wang, R. Krahe, and F.A. Wright Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions Am J Hum Genet 73 2003 748 767
41. S. Okada, E. Tokunaga, H. Kitao, and et al. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer Ann Surg Oncol 19 2012 1499 1507
42. S.A. Joosse, K.I. Brandwijk, L. Mulder, J. Wesseling, J. Hannemann, and P.M. Nederlof Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors Genes Chromosomes Cancer 50 2011 71 81
43. D.P. Silver, A.L. Richardson, A.C. Eklund, and et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol 28 2010 1145 1153
44. Y. Drew, E.A. Mulligan, W.T. Vong, and et al. Therapeutic potential of poly (ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2 J Natl Cancer Inst 103 2011 334 346